Is online prescribing a good idea? When is $2 billion not a lot of money? And what’s going to happen at J.P. Morgan 2023?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discuss the White House’s investment in biotech, a bellwether IPO, and the latest twist in the Merck-Seagen saga.
Correction: Last week, we mentioned the wrong company when discussing the drug LUMAKRAS. It is made by Amgen. We regret the error.
Sponsor content by Cytiva
mRNA has huge potential beyond vaccines. Could it help us cure deadly cancers?
There’s no question that mRNA helped bring Covid-19 vaccines to market at groundbreaking speeds. But what’s next? As scientists and clinicians set their sights on mRNA for therapies that could cure cancers and more, the biopharma industry will need to be ready to make them at the right scale. Learn more here.
No comments